Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO
Imaging Technology
OCTOBER 5, 2023
We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Chief Executive Officer of Blue Earth Diagnostics. Of the identified lesions, 16-25 were successfully verified (predominantly using follow-up imaging as SoT) as TP, providing a M1 VDR of 8.1-13%,
52 
Let's personalize your content